期刊文献+

西酞普兰与米氮平治疗老年抑郁症的对照研究 被引量:3

Comparative Study of Citalopram vs Mirtazapine in Treatment of Senile Depressive Patients
原文传递
导出
摘要 目的比较西酞普兰与米氮平治疗老年抑郁症的疗效和不良反应。方法将50例老年抑郁症患者随机分为西酞普兰组和米氮平组。分别给予西酞普兰和米氮平治疗,疗程8周,采用汉密尔顿抑郁量表(HAMD)及副反应量表(TESS)评定疗效和副反应。结果西酞普兰组和米氮平组显效率分别为84.0%和80.0%,二者疗效相当(P>0.05)。HAMD评分西酞普兰组第2周末显著下降,而米氮平组治疗第1周末即显著下降,副反应方面,西酞普兰组以口干、恶心、出汗增多、睡眠时间缩短为主,米氮平组则以嗜睡、眩晕、头疼为主。结论西酞普兰和米氮平均为治疗老年抑郁症的安全有效的药物。 Objective To compare the efficacy and safety of citalopram and mirtazapine in the treatment of senile depressive patients. Methods Fifty elderly patients with depression were randomly divided into citalopram group or mirtazapine group for 8 weeks respectively. The efficacy and side effects were evaluated by Hamilton depressive scale(HAMD)and treatment emergent symptom scale (TESS). Results The effective rates of citalopram and mirtazapine were 84.0% and 80. 0% respectively, there was no significant difference between two groups (P〉0. 05). After eight weeks of trent, the scores of HAMD were significantly lower than before treatment in both groups. The scores of HAMD decreased significantly at the end of the second week in citalopram group, but did at the end of the first week in mirtazaplne group. The inncidence of dry mouth, nausea, more sweat, shorten sleeping in citalopram group than in mirtazapine group, while the incidence of somnolence,dizzinese,hcadache in mirtazapine group than in citalopram group. Conclusion Citalopram and mirtazapine are safe and effective drug in the treatment of senile depression.
出处 《中国健康心理学杂志》 2006年第5期552-553,共2页 China Journal of Health Psychology
关键词 西酞普兰 米氮平 老年抑郁症 副反应量表 Citalopram Mirtazapine Senile depression TESS
  • 相关文献

参考文献8

  • 1朱建中,蒋幸衍,周德怡,张峰.米氮平与氟西汀治疗老年抑郁症对照研究[J].临床精神医学杂志,2005,15(5):277-278. 被引量:12
  • 2Patris M,Bouchard JM,Bougerol T,et al.Citalopram versus fluortine:a double-blind,comtrolled,multicentre,phase3 trial in patients with uniplar major depression treated in general paactice(J).Int Clin Psychopharmacol,1996,11:129~136
  • 3Klysener R,Bent-Hansen J,Hansen HL,et al.Efficacy of citalopram in the prevention of recurrent depression in elderly patients:placebo-controlled study of maintenance therapy(J).Bri J Psychiaty,2002,181:29 ~ 35
  • 4龚传鹏,徐汉明,向东方,周新芳.西酞普兰与米氮平治疗抑郁症对照研究[J].临床精神医学杂志,2005,15(3):154-155. 被引量:40
  • 5Turkey CL,Connell Y,Jones MP,et al.Risk factors late-life suicide:a prospective,community-based study (J).Am J Geriatric Psychiatry,2002,10:398~406
  • 6陈彦方,顾牛范.新编临床精神药物手册(M).济南:山东科技出版社,1997
  • 7Nobble S,Benfield P.Citalopram、A review of its pharmacology,clinical efficacy and tolerability in the treatment of depression (J).CNS Drugs,1997,8:410~431
  • 8Corman JM.Mirtazapine:clinical overview (J).J Clin Psychiatry,1999,60 (Suppl 17):9~13

二级参考文献12

共引文献47

同被引文献24

  • 1龚传鹏,徐汉明,向东方,周新芳.西酞普兰与米氮平治疗抑郁症对照研究[J].临床精神医学杂志,2005,15(3):154-155. 被引量:40
  • 2戢秋明,刘毅,陈冬峨.脑卒中后抑郁的相关因素分析[J].临床精神医学杂志,2006,16(3):149-150. 被引量:13
  • 3Kotila M, Numminen H,Waltimo O, et al. Depression after stroke: results of the finnstronke study[J]. Stroke, 1998,29:368-372.
  • 4Ono H, Shirakawa O, Nishiguchi N, et al. Serotomin 2A receptor genepolymorphism is not associated with completed suicide[J]. J Psychiatr Res,2001,35(3) :173- 176.
  • 5Nobble S,Benfield P,Citalopram. A review of its pharmacology, clinical efficacy and tolerahility in the treatment of depression[J]. CNS Drugs, 1997,8 : 410- 431.
  • 6Thawani H M, Yerramsetty P, Mannelli P, et al. Recent advances in poststroke depression. Curr Psychiatry Rep, 2007,9 : 225-231.
  • 7Bush B A. Major life evente as risk factors for poststroke depression. Brain lnj, 1999,13:131-137.
  • 8Ono H, Shirakawa O, Nishiguchi N, et al. Serotomin 2A receptor genepolymorphism is not associated with completed suicide. J Psychiatr Res, 2001,35(3):173-176.
  • 9Fava M. Weight gain and antidepressants. J cling sychiatry, 2000, 61(supple I 1):37-41.
  • 10中华医学会精神科分会.中国精神障碍分类与诊断标准[M].第3版.济南:山东科学技术出版社,2001:147-9

引证文献3

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部